查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球液体活检市场 - 按应用、目标疾病、循环生物标记类型、样本类型、发展阶段、产品类型、技术和主要地区：行业趋势和全球预测（2018-）2035）
市场调查报告书
商品编码
1398317

全球液体活检市场 - 按应用、目标疾病、循环生物标记类型、样本类型、发展阶段、产品类型、技术和主要地区：行业趋势和全球预测（2018-）2035）

Liquid Biopsy Market : Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, Stage of Development, Type of Product, & Technique, Key Geographical Regions: Industry Trends & Global Forecasts, 2018-2035
出版日期: | 出版商: Roots Analysis | 英文 331 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

到 2023 年，全球液体切片市场规模将达到 54 亿美元，在预测期内（2023-2035 年）复合年增长率为 15.2%。

癌症是全球第二大死因，也是全球健康日益受到关注的问题。 世界卫生组织 (WHO) 预测，到 2040 年，将有 1,630 万人死于癌症。 在癌症类型中，乳癌是全球最常见的癌症，其次是肺癌、大肠癌和摄护腺癌。 根据监测、流行病学和最终结果（SEER）计划的统计数据，女性终生乳癌诊断率预计为 18%，预计 2023 年将出现 297,790 例新病例。 为了应对这一日益增长的负担，许多癌症研究机构正在积极研究针对癌症早期检测和治疗的开创性方法和以患者为中心的策略。 癌症的早期发现是提高治疗效果和患者存活率的关键因素。 几十年来，组织活检一直是癌症诊断的标准。 然而，这种侵入性方法存在不适、疼痛和併发症风险等缺点，阻碍了其广泛使用。 然而，近年来，液体活检已被广泛研究并被认为是一种癌症诊断技术。 特别是在过去的十年里，液体活检平台取得了显着的进步，导致监管部门对微创血液检测的批准增加。 这些产品提供了一种早期癌症检测和患者监测的方法，并且易于使用且侵入性极小。 这些测试使用血液样本和体液（例如尿液和血浆）来识别基因突变和各种循环生物标记物，包括循环肿瘤 DNA、游离 DNA 和细胞外囊泡。 这种非侵入性评估正在彻底改变癌症治疗，特别是对于晚期癌症患者。

本报告分析了全球液体活检市场，提供了技术概述、市场最新状况、推动和抑制市场的主要因素、主要资本交易和商业联盟的近期趋势以及我们调查的总体情况市场规模趋势、按细分市场和地区划分的详细趋势以及主要公司的概况。

市场主要参与者

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

目录

第一章前言

第二章分析方法

第 3 章经济与其他专案特定考量

  • 分析概述
  • 市场动态

第 4 章执行摘要

第 5 章简介

  • 分析概述
  • 癌症统计数据和疾病负担
  • 早期发现癌症的重要性
  • 癌症筛检与诊断
  • 传统/侵入性癌症诊断测试
  • 需要非侵入性方法
  • 液体切片：循环生物标记的诊断
  • 与液体活检和非侵入性检测相关的成本和效益
  • 无创癌症诊断的最新智慧财产权趋势
  • 非侵入性癌症诊断面临的挑战
  • 未来前景

第 6 章非侵入性癌症筛检/诊断

  • 分析概述
  • 影像诊断
  • 筛选试验
  • 先进的非侵入性方法

第 7 章液体切片：市场情势

  • 分析概述
  • 液体切片产品：整体市场格局
  • 液体切片产品製造商
  • 液体活检产品：其他液体活检产品、套件和消耗品
  • 液体活检产品：合约服务提供商

第八章公司简介

  • 分析概述
  • 液体活检市场的其他主要参与者

第 9 章业务伙伴关係/协作

  • 分析概述
  • 业务合作
  • 液体切片：业务合作/协作

第十章融资与投资分析

  • 分析概述
  • 资金类型
  • 液体活检：融资和投资分析

第十一章产品竞争力分析

  • 分析概述
  • 调查方法
  • 先决条件与关键参数
  • 液体切片：产品竞争分析

第十二章主要製药公司的举措

  • 分析概述
  • 主要药厂

第十三章企业收购的主要目标

  • 分析概述
  • 分析范围/方法
  • 评分标准与重要先决条件
  • 北美的潜在收购目标
  • 欧洲的潜在收购目标
  • 亚太地区和世界其他地区 (ROW) 的潜在收购目标
  • 结论

第14章其他非侵入性癌症诊断

  • 分析概述
  • 非血液生物标记检测测试
  • FOBT 和粪便免疫化学检测 (FIT)
  • 色素病变测定
  • 基于粪便 DNA (sDNA) 的测试
  • 挥发性有机化合物（VOC）检测测试
  • 其他非侵入性癌症诊断：市场状况

第 15 章市场影响分析：驱动因素、限制、机会、挑战

  • 分析概述
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
  • 结论

第16章全球液体切片市场

  • 分析概述
  • 主要假设与分析技术
  • 全球非侵入性癌症诊断市场（2023-2035）
  • 全球液体活检市场：过去趋势（2018-2022）和预测（2023-2035）
  • 主要细分市场
  • 动态仪表板

第 17 章液体活检市场：按应用

  • 分析概述
  • 主要假设与分析技术
  • 癌症早期诊断：过去的趋势（2018-2022）和预测（2023-2035）
  • 病患监测：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 重复监测：过去的趋势（2018-2022 年）与预测（2023-2035 年）
  • 数据测量与验证

第 18 章液体切片市场：依目标疾病分类

  • 分析概述
  • 主要假设与分析技术
  • 膀胱癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 神经癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 乳癌：过去的趋势（2018-2022）和预测（2023-2035）
  • 子宫颈癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 头颈癌：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 白血病：过去的趋势（2018-2022）与预测（2023-2035）
  • 肝癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 肺癌：过去的趋势（2018-2022）和预测（2023-2035）
  • 黑色素瘤：过去的趋势（2018-2022 年）与预测（2023-2035 年）
  • 鼻咽癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 食道癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 卵巢癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 胰臟癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 摄护腺癌：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 肉瘤：过去的趋势（2018-2022）和预测（2023-2035）
  • 胃癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 甲状腺癌：过去的趋势（2018-2022）与预测（2023-2035）
  • 数据测量与验证

第 19 章液体切片市场：依循环生物标记类型划分

  • 分析概述
  • 主要假设与分析技术
  • 无细胞 DNA：过去趋势（2018-2022 年）与预测估计（2023-2035 年）
  • 循环肿瘤 DNA：过去趋势（2018-2022 年）和预测估计（2023-2035 年）
  • 细胞外囊泡：过去趋势（2018-2022 年）和预测估计（2023-2035 年）
  • 其他循环生物标记：历史趋势（2018-2022 年）和预测估计（2023-2035 年）
  • 数据测量与验证

第 20 章液体切片市场：依样本类型

  • 分析概述
  • 主要假设与分析技术
  • 血液/血浆样本：过去趋势（2018-2022 年）和预测（2023-2035 年）
  • 其他范例：过去的趋势（2018-2022 年）和预测（2023-2035 年）
  • 数据测量与验证

第 21 章液体切片市场：依最终使用者类型划分

  • 分析概述
  • 主要假设与分析技术
  • 医院：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 研究机构：过去趋势（2018-2022）与预测（2023-2035）
  • 其他最终用户：过去趋势（2018-2022 年）和预测（2023-2035 年）
  • 数据测量与验证

第 22 章液体切片市场：依主要地区划分

  • 分析概述
  • 主要假设与分析技术
  • 北美：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 欧洲：过去趋势（2018-2022 年）与预测（2023-2035 年）
  • 亚太地区和世界其他地区 (ROW)：过去趋势（2018-2022 年）和预测（2023-2035 年）
  • 数据测量与验证

第 23 章研究见解

  • 分析概述
  • 受访者公司的详细信息
  • 依受访者立场分析
  • 依产品组合类型进行分析
  • 依所提供的产品/服务类型进行分析
  • 依产品开发阶段进行分析
  • 依使用区域分析
  • 依预期市场规模进行分析

第24章结论

第 25 章管理考量

  • 章节概述
  • Foundation for the National Institutes of Health
  • Bahia Software
  • Genostics
  • Oncophenomics
  • Minomic International
  • IVDiagnostics
  • Tymora Analytical Operations
  • ProXeom
  • MiNDERA
  • Resolution Bioscience
  • Nanostics
  • DermTech
  • iCellate Medical
  • VolitionRx
  • OncoDNA
  • LCM Genect
  • Sienna Cancer Diagnostics

第 26 章附录 1：表格资料

第 27 章附录 2：公司与组织名单

简介目录
Product Code: RA100460

The global liquid biopsy market is valued at USD 5.4 billion in 2023 growing at a CAGR of 15.2% during the forecast period 2023-2035.

Cancer stands as the second most prevalent cause of mortality worldwide, presenting an escalating global health concern. Projections by the World Health Organization (WHO) estimate a staggering 16.3 million cancer-related fatalities by 2040. Among the spectrum of cancer types, breast cancer leads as the most commonly occurring globally, trailed by lung, colorectal, and prostate cancers. Statistical data from the Surveillance, Epidemiology, and End Results (SEER) program indicate an anticipated 18% lifetime diagnosis rate for women regarding breast cancer, with an estimated 297,790 new cases anticipated in 2023. To counteract this mounting burden, numerous cancer research institutions actively engage in pioneering methodologies and patient-centric strategies targeting early detection and treatment of cancer. Early identification of cancer constitutes a pivotal factor in bolstering treatment efficacy and augmenting patient survival rates. For decades, tissue biopsy has stood as the benchmark for cancer diagnosis. However, the drawbacks inherent in this invasive procedure-ranging from discomfort, pain to the risk of complications-have impeded its widespread adoption. Nonetheless, extensive exploration into liquid biopsy over recent years has propelled its acknowledgment as a viable diagnostic technique for cancer. The last decade, in particular, has witnessed remarkable advancements in liquid biopsy platforms, resulting in increased regulatory endorsements for minimally invasive blood-based tests. These products present an avenue for early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. Leveraging blood samples or other bodily fluids like urine or plasma, these tests discern genetic mutations and various circulating biomarkers, encompassing circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are revolutionizing cancer care, particularly for individuals in advanced cancer stages.

Key Market Segments:

Application

  • Early Cancer Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

Type of Target Disease Indication

  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Lung Cancer
  • Prostate cancer
  • Others

Type of Circulating Biomarker

  • Cell Free DNA
  • Cell Free RNA
  • Circulating Tumor DNA
  • Extracellular Vesicles
  • Other Circulating Biomarkers

Type of Sample

  • Blood / Plasma
  • Other Analytes

End User

  • Hospitals
  • Research Institutes
  • Others

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the liquid biopsy market based on application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • A detailed outline of the research approach employed for studying the liquid biopsy market and non-invasive cancer diagnostics. This includes methodologies, assumptions, and quality control measures adopted to ensure the reliability and accuracy of findings.
  • Examination of historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements that influence the overall liquid biopsy market.
  • Concise summary capturing key insights from the research, providing a high-level view of the current status of the liquid biopsy market and its anticipated evolution in the short, mid, and long terms.
  • Overview of cancer statistics, emphasizing the global disease burden, the significance of early cancer detection and screening, and insights into different types of circulating biomarkers based on their functionality. Additionally, exploration of emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their importance.
  • Emphasis on the necessity and significance of non-invasive cancer diagnostics, inclusive of various imaging techniques, screening assays, advanced diagnostic approaches, along with their respective advantages and disadvantages.
  • Detailed assessment of the liquid biopsy product market based on multiple parameters like development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and players involved.
  • Tabulated profiles of leading liquid biopsy companies focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
  • Examination of recent collaborations within the liquid biopsy market, considering parameters such as partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
  • In-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
  • Detailed evaluation of liquid biopsy product competitiveness based on supplier strength, product attributes, company size, and technological advancements.
  • Comprehensive analysis of initiatives by major pharmaceutical companies, focusing on areas of interest, stages of development, product types, target indications, and application areas.
  • Review of historical acquisition activities since 2016, identifying potential acquisition targets within the industry.
  • Detailed insight into various non-invasive diagnostic tests, besides liquid biopsies, offered by different companies for cancer screening and early detection.
  • In-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the liquid bipsy market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Chapter Overview
  • 1.2. Project Objectives
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Cancer Statistics and Burden of the Disease
  • 5.3. Importance of Early Cancer Detection
  • 5.4. Cancer Screening and Diagnosis
  • 5.5 Conventional Invasive Cancer Diagnostic Tests
    • 5.5.1. Biopsy
    • 5.5.2. Fine Needle Aspiration Biopsy
    • 5.5.3. Core Needle Aspiration Biopsy
    • 5.5.4. Vacuum-Assisted Biopsy
    • 5.5.5. Image Guided Biopsy
    • 5.5.6. Sentinel Node Biopsy
    • 5.5.7. Surgical Biopsy
    • 5.5.8. Endoscopic Biopsy
    • 5.5.9. Bone Marrow Biopsy
    • 5.5.10. Endoscopy
  • 5.6. Need for Non-Invasive Approaches
  • 5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
    • 5.7.1 Circulating Tumor Cells
    • 5.7.2. Circulating Tumor DNA/ Cell Free DNA
    • 5.7.3. Exosomes
  • 5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
  • 5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
  • 5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
  • 5.11. Future Perspectives

6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

  • 6.1. Chapter Overview
  • 6.2. Diagnostic Imaging
    • 6.2.1. Magnetic Resonance Imaging (MRI)
    • 6.2.2. Mammography
    • 6.2.3. Bone Scan
    • 6.2.4. Computerized Tomography (CT) Scan
    • 6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
    • 6.2.6. Ultrasound
    • 6.2.7. X-ray Radiography (Barium Enema)
  • 6.3. Screening Assays
    • 6.3.1. Circulating Tumor Marker Test
    • 6.3.2. Digital Rectal Exam (DRE)
    • 6.3.3. Fecal Occult Blood Test (FOBT)
    • 6.3.4. Multigated Acquisition (MUGA) Scan
    • 6.3.5. Papanicolaou Test and Human Papilloma Virus Test
  • 6.4. Advanced Non-Invasive Approaches
    • 6.4.1. Cytogenetic / Gene Expression Studies
    • 6.4.2. Molecular Signature-based Non-Invasive Methods
    • 6.4.3. Saliva-based Oral Cancer Diagnostics
    • 6.4.4. Vital Staining
    • 6.4.5. Optical Biopsy
    • 6.4.6 Other Diagnostic Techniques

7. LIQUID BIOPSY: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Liquid Biopsy Products: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Type of Product
    • 7.2.3. Analysis by Type of Sample
    • 7.2.4. Analysis by Type of Technique
    • 7.2.5. Analysis by Type of Circulating Biomarker
    • 7.2.6. Analysis by Tumor
    • 7.2.7. Analysis by Target Disease Indication
    • 7.2.8. Analysis by Application
    • 7.2.9. Analysis by Application Area
  • 7.3. Liquid Biopsy Product Manufacturers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters (Region)
    • 7.3.3. Analysis by Location of Headquarters (Country)
    • 7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
  • 7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
  • 7.5. Liquid Biopsy Products: Contract Service Providers

8. COMPANY PROFILES

  • 8.1. Chapter Overview
    • 8.2.1. Amoy Diagnostics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Product Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. ArcherDX
      • 8.2.2.1. Company Overview
      • 8.2.2.2 Product Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. DiaCarta
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Product Portfolio
      • 8.2.3.3 Recent Developments and Future Outlook
    • 8.2.4. Integrated DNA Technologies
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Product Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5 MDNA Life Sciences
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Information
      • 8.2.5.3 Product Portfolio
      • 8.2.5.4. Recent Developments and Future Outlook
    • 8.2.6. NeoGenomics
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Product Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. ONCODE Scientific
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Product Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. QIAGEN
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Information
      • 8.2.8.3. Product Portfolio
      • 8.2.8.4. Recent Developments and Future Outlook
    • 8.2.9. ScreenCell
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Information
      • 8.2.9.3. Product Portfolio
      • 8.2.9.4. Recent Developments and Future Outlook
    • 8.2.10. Thermo Fisher Scientific
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Information
      • 8.2.10.3. Product Portfolio
      • 8.2.10.4. Recent Developments and Future Outlook
  • 8.3. Other Leading Players in Liquid Biopsy Market
    • 8.3.1. Biocartis
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Product Portfolio
    • 8.3.2. Cell Search
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Product Portfolio
    • 8.3.3. CellMax Life
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Product Portfolio
    • 8.3.4. Datar Cancer Genetics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Product Portfolio
    • 8.3.5. EONE-DIAGNOMICS Genome Center
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Product Portfolio
    • 8.3.6. Exosome Diagnostics
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Product Portfolio
    • 8.3.7. GeneCast Biotechnology
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Product Portfolio
    • 8.3.8. Inivata
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Product Portfolio
    • 8.3.9. Lucence
      • 8.3.90.1. Company Overview
      • 8.3.9.2. Product Portfolio
    • 8.3.10. Miltenyi Biotec
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Product Portfolio
    • 8.3.11. OncoDNA
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Product Portfolio
    • 8.3.12. PANAGENE
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Product Portfolio
    • 8.3.13. Personal Genome Diagnostics
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Product Portfolio
    • 8.3.14. Predicine
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Product Portfolio
    • 8.3.15. Tecan
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Liquid Biopsy: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Year of Partnership and Type of Partner
    • 9.3.6. Analysis by Type of Partnership and Type of Partner
    • 9.3.7. Analysis by Type of Circulating Biomarker
    • 9.3.8. Analysis by Target Disease Indication
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Local and International Agreements
      • 9.3.10.2 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Liquid Biopsy: Funding and Investment Analysis
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis of Amount Invested by Year
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis by Year and Type of Funding
    • 10.3.6. Analysis by Type of Circulating Biomarker
    • 10.3.7. Analysis by Target Disease Indication
    • 10.3.8. Analysis by Application Area
    • 10.3.9. Analysis by Geography
    • 10.3.10. Most Active Players: Analysis by Number of Funding Instances
    • 10.3.11. Most Active Players: Analysis by Amount Raised
    • 10.3.12. Most Active Investors: Analysis by Number of Funding Instances

11. PRODUCT COMPETITIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Methodology
  • 11.3. Assumptions and Key Parameters
  • 11.4. Liquid Biopsy: Product Competitiveness Analysis
    • 11.4.1. Liquid Biopsy Assay Kits
      • 11.4.1.1. Products Offered by Players based in North America
      • 11.4.1.2. Products Offered by Players based in Europe
      • 11.4.1.3. Products Offered by Players based in Asia-Pacific
      • 11.4.1.4. Products Offered by Players based in Rest of the World
    • 11.4.2. Liquid Biopsy Devices
      • 11.4.2.1. Products Offered by Players based in North America
      • 11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
    • 11.4.3. Liquid Biopsy Software

12. BIG PHARMA INITIATIVES

  • 12.1. Chapter Overview
  • 12.2. Top Pharmaceutical Companies
    • 12.2.1. Analysis by Type of Initiative
    • 12.2.2. Analysis by Stage of Development
    • 12.2.3. Analysis by Type of Product
    • 12.2.4. Analysis by Type of Circulating Biomarker
    • 12.2.5. Analysis by Target Disease Indication
    • 12.2.6. Analysis by Application
    • 12.2.7. Analysis by Application Area

13. KEY ACQUISITION TARGETS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Scoring Criteria and Key Assumptions
  • 13.4. Potential Acquisition Targets in North America
  • 13.5. Potential Acquisition Targets in Europe
  • 13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
  • 13.7. Concluding Remarks

14. OTHER NON-INVASIVE CANCER DIAGNOSTICS

  • 14.1. Chapter Overview
  • 14.2. Non-Blood-based Biomarker Detection Tests
  • 14.3. FOBT and Fecal Immunochemical Tests (FIT)
  • 14.4. Pigmented Lesion Assays
  • 14.5. Stool DNA (sDNA)-based Tests
  • 14.6. Volatile Organic Compound (VOC) Detection Tests
  • 14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. GLOBAL LIQUID BIOPSY MARKET

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
  • 16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 16.4.1. Scenario Analysis
  • 16.5. Key Market Segmentations
  • 16.6. Dynamic Dashboard

17. LIQUID BIOPSY MARKET, BY APPLICATION

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.6. Data Triangulation and Validation

18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.20. Data Triangulation and Validation

19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.7. Data Triangulation and Validation

20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation and Validation

21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation and Validation

22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.6. Data Triangulation and Validation

23. SURVEY INSIGHTS

  • 23.1. Chapter Overview
  • 23.2. Company Specifics of Respondents
  • 23.3. Analysis by Seniority Level of Respondents
  • 23.4. Analysis by Type of Product Portfolio
  • 23.5. Analysis by Type of Products / Services Offered
  • 23.6. Analysis by Stage of Development of Product
  • 23.7. Analysis by Application Area
  • 23.8. Analysis by Likely Market Size

24. CONCLUSION

25. EXECUTIVE INSIGHTS

  • 25.1. Chapter Overview
  • 25.2. Foundation for the National Institutes of Health
    • 25.2.1. Company Snapshot
    • 25.2.2. Interview Transcript
  • 25.3. Bahia Software
    • 25.3.1. Company Snapshot
    • 25.3.2. Interview Transcript
  • 25.4. Genostics
    • 25.4.1. Company Snapshot
    • 25.4.2. Interview Transcript
  • 25.5. Oncophenomics
    • 25.5.1. Company Snapshot
    • 25.5.2. Interview Transcript
  • 25.6. Minomic International
    • 25.6.1. Company Snapshot
    • 25.6.2. Interview Transcript
  • 25.7. IVDiagnostics
    • 25.7.1. Company Snapshot
    • 25.7.2. Interview Transcript
  • 25.8. Tymora Analytical Operations
    • 25.8.1. Company Snapshot
    • 25.8.2. Interview Transcript
  • 25.9. ProXeom
    • 25.9.1. Company Snapshot
    • 25.9.2. Interview Transcript
  • 25.10. MiNDERA
    • 25.10.1. Company Snapshot
    • 25.10.2. Interview Transcript
  • 25.11. Resolution Bioscience
    • 25.11.1. Company Snapshot
    • 25.11.2. Interview Transcript
  • 25.12. Nanostics
    • 25.12.1. Company Snapshot
    • 25.12.2. Interview Transcript
  • 25.13. DermTech
    • 25.13.1. Company Snapshot
    • 25.13.2. Interview Transcript
  • 25.14. iCellate Medical
    • 25.14.1. Company Snapshot
    • 25.14.2. Interview Transcript
  • 25.15. VolitionRx
    • 25.15.1. Company Snapshot
    • 25.15.2. Interview Transcript
  • 25.16. OncoDNA
    • 25.16.1. Company Snapshot
    • 25.16.2. Interview Transcript
  • 25.17. LCM Genect
    • 25.17.1. Company Snapshot
    • 25.17.2. Interview Transcript
  • 25.18. Sienna Cancer Diagnostics
    • 25.18.1. Company Snapshot
    • 25.18.2. Interview Transcript

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS